^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | rilvegostomig (AZD2936) (PD1 inhibitor, TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Excerpt:
...- Documented PD-L1 expression by PD-L1 IHC per local report....
Trial ID:
Source:
Title:
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer
Excerpt:
...Part Cand Part D: Stage IV squamous or non-squamous NSCLC not amenable tocurative surgery or radiation.- Documented PD-L1 expression by PD-L1 IHC per local report.- Confirmed progression during treatment with a CPI-including regimen(Part A, Part B).- No prior IO treatment for metastatic NSCLC (Part C, Part D).- ECOG performance status of 0 or 1 at enrolment.- Life expectancy of = 12 weeks at enrolment.- Have at least 1 measurable lesion per RECIST v1.1- Adequate bone marrow, liver and kidney function.`...
Trial ID:
Less C2 evidence
Source:
Title:
1446P - Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Published date:
10/16/2023
Excerpt:
Pts in the initial phase of this open-label, multicentre study had stage III unresectable or stage IV NSCLC, PD-L1 tumour proportion score ≥1%...Rilvegostomig was well tolerated and had antitumour activity in heavily pretreated pts who had progressed on CPI therapy.
Trial ID:
